– USA, WA – EndoGastric Solutions, Inc. today announced the appointment of Darin Hammers to its Board of Directors as President and CEO, replacing Skip Baldino, who stepped down.
About Darin Hammers
His experience includes over 30 years of increasing leadership roles in the medical device industry. Most recently, he has served as CEO of DYSIS Medical since September 2018. Before joining DYSIS, Mr. Hammers served as the President and CEO of Cogentix Medical, which Laborie acquired in April 2018. He joined Cogentix’s predecessor company, Uroplasty, as VP of Global Sales in January 2013. He was promoted to COO before being named President and CEO in July 2016. Before joining Uroplasty, he was VP of Sales for Bard Medical Division of C.R. Bard based in Covington, GA, focused on Urology/Gynecology care products. Mr. Hammers also spent more than 12 years with Boston Scientific in various sales leadership positions and six years at ETHICON.
“I am excited to join EGS at this pivotal point in the Company’s commercial evolution, and l look forward to working with this highly-experienced management team and board of directors,” said Darin Hammers. “Additionally, the $18M investment into the Company will provide us with added fuel to drive future growth.
He received his bachelor’s degree in Marketing from the University of Southern Indiana, and a master’s in Business Administration from Emory University – Goizueta Business School.
About EndoGastric Solutions
Based in Redmond, Washington, EndoGastric Solutions, Inc. is a medical device company developing and commercializing innovative, evidence-based, incisionless surgical technologies for treating GERD, including the EsophyX device used to perform the TIF 2.0 procedure.
The TIF 2.0 procedure is a safe and effective alternative to surgery for treating GERD and GERD symptoms. Based on data from more than 140 peer-reviewed publications, most patients who received the TIF 2.0 procedure were able to eliminate the use of daily medications for up to five years following their procedure. Over 35,000 TIF 2.0 procedures have been performed worldwide, with a good safety profile.
EGS has closed on a significant financing of $18M to help further drive the growth and adoption of the TIF 2.0 procedure to help patients suffering from Gastroesophageal Reflux Disease.
For more information: https://www.endogastricsolutions.com/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.